Alnylam Pharmaceuticals Inc (ALNY)vsWPP PLC ADR (WPP)
ALNY
Alnylam Pharmaceuticals Inc
$295.05
-0.29%
HEALTHCARE · Cap: $39.51B
WPP
WPP PLC ADR
$18.97
+1.12%
COMMUNICATION SERVICES · Cap: $4.05B
Smart Verdict
WallStSmart Research — data-driven comparison
WPP PLC ADR generates 216% more annual revenue ($13.55B vs $4.29B). ALNY leads profitability with a 12.6% profit margin vs -1.6%. ALNY appears more attractively valued with a PEG of 0.51. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
WPP
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.6%
Fair Value
$2410.60
Current Price
$295.05
$2115.55 discount
Margin of Safety
+75.6%
Fair Value
$75.12
Current Price
$18.97
$56.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 90 in profit
Revenue surging 96.4% year-over-year
Growing faster than its price suggests
Strong operational efficiency at 23.0%
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 36.6x book value
Operating margin of 2.2%
Weak financial health signals
Expensive relative to growth rate
ROE of -5.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth, PEG Ratio. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.51 suggests the stock is reasonably priced for its growth.
Bull Case : WPP
The strongest argument for WPP centers on Free Cash Flow.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 74.2x leaves little room for execution misses.
Bear Case : WPP
The primary concerns for WPP are Operating Margin, Piotroski F-Score, PEG Ratio. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
ALNY profiles as a growth stock while WPP is a turnaround play — different risk/reward profiles.
WPP carries more volatility with a beta of 0.65 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
WPP generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 32/100) and 96.4% revenue growth. WPP offers better value entry with a 75.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
WPP PLC ADR
COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA
WPP plc, a creative transformation company, provides communications, expertise, trade and technology services in North America, the UK, Western Continental Europe, Asia Pacific, Latin America, Africa, the Middle East, and Central and Eastern Europe. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?